New hope for advanced tumors: BL-M07D1 enters human testing
NCT ID NCT05631964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, BL-M07D1, in about 26 people with advanced digestive tract or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants must be at least 18 years old and expected to live at least 3 more months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC DIGESTIVE TRACT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University ShangHai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New national registry aims to unlock secrets of Ultra-Rare childhood cancers
- New drug targets rare genetic cancers in early trial
- Experimental combo targets Hard-to-Treat bone cancer
- New pill JAB-3312 tested in patients with advanced cancers
- New drug candidate BL-M05D1 enters early human trials for tough cancers